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It is clear that A Disintegrin And Metalloproteinase with ThromboSpondin motif (ADAMTS)-5 is the
major aggrecanase in mouse cartilage, however it is not at all clear which enzyme is the major
aggrecanase in human cartilage. Identifying the human aggrecanase is difﬁcult because multiple, inde-
pendent, molecular processes determine the ﬁnal level of enzyme activity. As investigators, we have
good methods for measuring changes in the expression of ADAMTS mRNA, and good methods for
detecting aggrecanase activity, but no methods that distinguish the source of the activity. In between
gene expression and enzyme action there are many processes that can potentially enhance or inhibit the
ﬁnal level of activity. In this editorial we discuss how each of these processes affects ADAMTS activity and
argue that measuring any one process in isolation has little value in predicting overall ADAMTS activity
in vivo.
Crown Copyright  2010 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. All rights reserved.Introduction
It is now over a decade since A Disintegrin And Metal-
loproteinase with ThromboSpondin motif (ADAMTS)-41, and
ADAMTS-52 were identiﬁed as aggrecanases, based on their ability
to cleave at the Glu373Y 374Ala bond in the aggrecan interglobular
domain (IGD). Since then ADAMTS-1, -8, -9, -15, -16 and -18 family
members have also been identiﬁed as aggrecan-degrading enzymes
in vitro, but none have seriously challenged ADAMTS-4 and
ADAMTS-5 as the candidate human aggrecanases because these
have substantially greater aggrecan-degrading activity in vitro.
ADAMTS-4 and -5 are expressed in human cartilage and in many
cases their expression levels are increased in joint disease, and at
sites of localised aggrecan loss. The results of a recent genome-wide
association study revealed eight polymorphisms in the ADAMTS-5
gene, two of which caused amino acid changes. However neither
polymorphism was associated with difference in susceptibility to
osteoarthritis (OA) in a large cohort of patients3.
It is not clear whether ADAMTS-4 or ADAMTS-5 is the aggre-
canase in human cartilage. Indeed there is evidence suggesting that
both aggrecanases have key roles in degrading aggrecan in vivo4.
Identifying the human aggrecanase is a major challenge because
the ﬁnal level of enzyme activity is determined by multiple, inde-
pendent and interacting molecular processes, including promotero: University of Melbourne,
esearch Institute, Royal Chil-
tralia.
Fosang).
010 Published by Elsevier Ltd onactivity, epigenetic modiﬁcations, regulation by non-coding RNA
(ncRNA) including microRNA (miRNA), and alternative splicing. At
the protein level, ADAMTS activity is determined by the summed
effect of prodomain processing, C-terminal processing, the avail-
ability and binding of endogenous enhancers or inhibitors, and the
extent of glycosylation on both the aggrecan substrate and the
enzymes themselves (Fig. 1). We herein discuss how each of these
processes affects ADAMTS activity and argue that measuring any
one parameter in isolation is an inadequate surrogate for deter-
mining the identity of the human aggrecanase.Regulating ADAMTS-4 and -5 mRNA expression
Apart from activity studies that tell us a great deal about
aggrecanases collectively, the most abundant studies on human
ADAMTS-4 and -5 are those that have analysed mRNA expression
either in vitrowith and without catabolic stimuli, or immediately ex
vivo, from normal or OA cartilage. Most4e8 but not all9,10 the in vitro
studies in human cartilage or chondrocytes found that ADAMTS-4
mRNA was induced by catabolic cytokines such as interleukin-1b
(IL-1b) or Tumor necrosis factor a (TNFa) and that ADAMTS-5
mRNAwas not regulated by cytokines but expressed constitutively.
These ﬁndings differ from most animal studies which show that
ADAMTS-5 mRNA expression is upregulated by catabolic cytokines
(reviewed in Ref. 11).
The absence of ADAMTS-4 and -5 in early OA gene proﬁling
studies12e14 suggests that on a global scale, these enzymes are
lowly expressed. Other expression studies focussing speciﬁcally onbehalf of Osteoarthritis Research Society International. All rights reserved.
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Fig. 1. Aggrecanase activity is determined by multiple molecular processes.
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expressed than ADAMTS-4 in both normal and OA cartilage5,15.
Some studies report increased expression of both ADAMTS-4 and
ADAMTS-5 in knee cartilage from patients with late, but not early
stage OA5,16. Other studies report that only ADAMTS-4 mRNA is
increased in knee cartilage7,17 or hips18 measured at the time of
joint replacement, while others report decreases in both ADAMTS-4
and -5 mRNA in patients with late stage hip OA15. Given the
differences between the aetiopathogenesis of hip and knee OA19, it
is not surprising that ADAMTS expression differs between knee and
hip joints in humans15 and presumably differs also with stage of
disease, although this has not been systematically examined.
ADAMTS expression in cartilage represents only one part of the
total joint picture, since ADAMTS enzymes are expressed in joint
capsule and meniscus, as well as in synovium where ADAMTS
expression is particularly well documented20e28. In distinct
contrast to cartilage, both ADAMTS-4 and -5 are expressed consti-
tutively in synovium and their expression by synovial ﬁbroblasts is
not regulated by IL-1 in vitro20,21,29. Expression proﬁling studies
show that ADAMTS-4 and -5 are signiﬁcantly decreased in syno-
vium from patients with hip OA, compared with the levels in
synovium from patients with neck of femur fractures26. A different
study using synovium from patients with cruciate ligament injury
as the non-arthritic comparator showed that ADAMTS-4, but not
ADAMTS-5 was signiﬁcantly increased in rheumatoid arthritis (RA)
patients; however, in this study neither ADAMTS-4 nor ADAMTS-5
expression levels were changed in OA synovium20. Not surprisingly,
synovial ﬁbroblasts from mouse joints express a different reper-
toire of aggrecan-degrading activities compared with mouse
chondrocytes, based on the pattern of neoepitopes detected by
Western blotting29. During episodes of synovial hyperplasia it is
entirely possible that synovial ﬁbroblasts might be the major
source of aggrecanases within the joint, and that synovial-derived
enzymes mediate aggrecanolysis in cartilage29. There is less liter-
ature available on aggrecanase activity in the meniscus, however
one study has shown that mechanical compression of meniscal
tissue in vitro up-regulates ADAMTS-5 mRNA and down-regulates
ADAMTS-4 mRNA expression23. The effect of theses changes on
aggrecanase activity in the meniscus is not known.
ADAMTSmRNA expression and activity can be directly regulated
by transforming growth factor-b (TGF-b)6,20 and indirectly modu-
lated by ﬁbroblast growth factor-2 (FGF-2), S100A8 and high
molecular weight hyaluronan (HA). TGF-b is well known for its
anabolic role in matrix metabolism, but TGF-b can also promote
joint destruction30. TGF-b strongly up-regulates ADAMTS-4 mRNA
and protein expression in human synovial ﬁbroblasts, whereasADAMTS-5 is not regulated by this growth factor20. Another growth
factor, FGF-2, inhibits IL-1-induced expression of ADAMTS-4 and -5
in primary human chondrocytes without inhibiting IL-1 actions on
other target molecules10. Conversely, the stress-induced calcium-
binding protein, S100A8, enhances IL-1-induced ADAMTS-5
expression in mouse cartilage, resulting in increased NITEGE373
immunoreactivity and aggrecan loss31. In other studies, high
molecular weight HA (Mre2700 kDa) can decrease IL-1a-induced
expression of ADAMTS-4 mRNA and protein, without inhibiting
ADAMTS-4 expression directly8; the mechanism is unclear. In
summary, ADAMTS-4 and -5 mRNA can be up- or down-regulated
by a variety of modulators typically found in arthritic joints.
However we emphasise that to date, there are no corresponding
studies linking increased mRNA expression with increased
ADAMTS-4 or ADAMTS-5 activity.
In addition to modulators that are known, or thought, to act via
intracellular signalling pathways, at least two transcription factors
can potentially modify aggrecanase gene expression by direct
binding to the ADAMTS-4 or -5 gene promoters. The human
ADAMTS-4 promoter has two putative binding sites for the tran-
scription factor nuclear factor of activated T cells-p (NFATp) and
eight putative binding sites for the Runx family of transcription
factors32. Over-expression of either NFATp or Runx2 in cells
expressing 4.5 kb of the ADAMTS-4 promoter resulted in trans-
activation of the ADAMTS-4 promoter32. Similarly, analysis of 2.6 kb
of the human ADAMTS-5 promoter revealed four putative binding
sites for the family of Runx transcriptions factors and Runx2
transactivated the ADAMTS-5 promoter in vitro33. The in vivo
inﬂuence of Runx2 and NFATp on aggrecanase activity via the
ADAMTS-4 or ADAMTS-5 promoter is unknown.
ADAMTS-4 and -5 regulation by alternative splicing,
epigenetics and ncRNA
There are other pre-translational mechanisms for modulating
aggrecanase activity independently of mRNA expression; these
include alternative splicing of the ADAMTS transcripts, regulation
by ncRNAs including miRNA and gene silencing (or unsilencing) by
epigenetic modiﬁcations to DNA and histones.
An alternatively spliced transcript of ADAMTS-4 has been
identiﬁed in synovium from OA patients27. The splice variation
occurs between exons 8 and 9 to create a longer protein which
diverges from wildtype ADAMTS-4 near the start of the spacer
region, after Arg696. There is no information on the abundance of
this transcript in synovium, its expression in cartilage and other
joint tissues, or its expression in other patient groups. It will be
fascinating to determine the efﬁcacy of the ADAMTS-4 splice
variant as an aggrecan-degrading enzyme. The splice variant is
likely to have altered enzyme activity, given the importance of the
spacer region in conferring maximum aggrecanolytic activity on
ADAMTS-434. There is no evidence for alternatively spliced tran-
scripts of ADAMTS-5.
The genomes of eukaryotes studied to date are almost entirely
transcribed, leading to vast numbers of ncRNAs with unknown
functions35. These ncRNAs and miRNAs represent a new frontier in
the molecular biology of human disease. miRNAs primarily affect
gene expression by inhibiting protein translation, without affecting
transcription. Much less is known about ncRNAs in terms of actions
in vivo but they are thought to have important roles in epigenetic,
transcriptional and post-transcriptional regulation of gene
expression (reviewed in Ref. 35).
It is clear that miRNAs provide important regulatory checks in
the immune system and inﬂammatory reactions, and a 16-miRNA
gene signature that is differentially expressed in OA has recently
been described36. Two independent studies have now reported the
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Fig. 2. The domain structure of ADAMTS-4 and ADAMTS-5. The schematic shows the
sequential arrangement of the signal peptide (sig), prodomain (Pro), catalytic domain
(Cat), disintegrin domain (Dis), ﬁrst thrombospondin-like motif (TS), the cysteine-rich
domain (Cys) and spacer domain (Spac). ADAMTS-5 has an additional thrombospondin
motif at its C-terminus.
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controls36,37. miR140/mice have signiﬁcantly increased levels of
ADAMTS-5 mRNA and increased aggrecan loss in vitro, compared
with wildtypemice38. miR140 is also predicted to target ADAMTS-4
and matrix metalloproteinase-13 (MMP-13)36,39. There is no data
comparing the effects of miR140 on ADAMTS-4- vs ADAMTS-5-
mediated aggrecanase activity in any species. Mimic miRNAs and
anti-miRNAs are of interest for the treatment of cancers however
the study of ncRNAs in cartilage, and their inﬂuence in OA and
inﬂammatory arthritis, is very much in its infancy.
Epigenetic modiﬁcations include changes in the methylation
status of CpG sites in gene promoters, and the acetylation and
deacetylation of histone proteins. Epigenetic changes determine
whether genes are silenced or transcribed and they lead to heri-
table and permanent alterations in gene expression. In arthritic
diseases, epigenetic changes can potentially escalate disease
progression through, for example, synovial hyperplasia in RA, or
cell proliferation within chondrocyte clusters that are typically
seen in human OA. Recent studies have shown that aberrant
expression of ADAMTS-4 is associated with loss of DNA methyla-
tion at speciﬁc CpG sites in the ADAMTS-4 promoter18,40.
Furthermore, a related study comparing young (23 years of age)
and old (80e90 years of age) OA cartilage, with non-arthritic age-
matched comparators, suggests that ageing alone does not account
for the epigenetic unsilencing in OA. This is based on the ﬁnding
that the association between ADAMTS-4 expression and deme-
thylation of the ADAMTS-4 promoter was a consistent feature of
both the young and old OA cartilage41. There are examples of
abnormal ADAMTS-5 promoter methylation in some cancers42. In
the future it will be important to characterise the epigenetic
changes in ADAMTS-4 and -5 and correlate them with changes in
aggrecan-degrading activity.
ADAMTS-4 and -5 activation by N-terminal processing
Two early studies pointed to the possibility that aggrecanase
activity might be controlled at a post-translational level. Flannery
and colleagues showed that retinoic acid-induced aggrecanase
activity was increased in bovine chondrocytes with no concomitant
increase in mRNA levels for any ADAMTS homologues43. In a sepa-
rate study, Pratta and colleagues showed that IL-1-induced
ADAMTS-4 activity was increased in bovine chondrocytes in the
absence of any detectable increase in ADAMTS-4 protein produc-
tion44; these investigators concluded that enzyme activation was
responsible for the increased activity of constitutively expressed
ADAMTS-4.
ADAMTS-4 and -5 are synthesised as latent proenzymes and
retained in their inactive state by interactions between their pro
and catalytic domains. The mechanism by which the prodomains
maintain ADAMTS latency is unknown but it is unlikely to be via the
well known cysteine switch mechanism found in the matrix met-
alloproteinase family45. Instead, the ADAMTS-4 and -5 prodomains
might directly inhibit enzyme activation via a non-cysteine switch
mechanism, similar to that seen for ADAM1746,47.
Furin, or furin-like proprotein convertases (PC), has major roles
in activating ADAMTS enzymes. Furin, PC7 and PC5A activate
recombinant ADAMTS-4 or -548e51 and Malfait et al. have used
silencing RNA (siRNA) to show that PACE4 activates aggrecanases in
OA and cytokine-stimulated human cartilage in culture52. Cleavage
occurs at the multibasic furin/PC recognition sites located at
RRAKR212 in human ADAMTS-41 and RRRRR261 in human ADAMTS-
52,50. Importantly, N-terminal processing and activation can be
mediated by more than one PC at more than one cellular location,
since PCs are located in the trans Golgi network, in endosomes, at
the cell surface53 and in the extracellular matrix50. Extracellularand/or cell surface activation has been reported for ADAMTS-550,52
and both intracellular49 and cell surface51 activation has been
reported for ADAMTS-4.
Variables in the ADAMTS activation process (which PC, which
cellular site) could signiﬁcantly inﬂuence the efﬁciency of enzyme
activation and alter enzyme activity, independent of mRNA levels.
Other variables include the fact that PCs themselves are subject to
regulated expression and selective glycosylation of PCs can affect
their activity.
Regulation of ADAMTS-4 and -5 activities by C-terminal
processing
Processing to removeC-terminal ancillary domainsof ADAMTS-4
and -5 is likely to be a common mechanism for regulating aggreca-
nase activity. Truncated forms of both enzymes are consistently
found in tissue extracts and experimental systems16,17,20,21,54,55
following local proteolysis54 or autolysis56,57. For example, the
major form of ADAMTS-5 in normal human synovium is the 70 kDa
mature form, whereas synovium fromRA patients is predominantly
the 53 kDa form lacking the last thrombospondin module and the
spacer domain20. Theminimumdomain composition for amolecule
containingaggrecan-degrading activity, inbothADAMTS-4and -5, is
the catalytic domain, the disintegrin domain and the ﬁrst throm-
bospondin module (Fig. 2); recombinant truncates lacking the ﬁrst
thrombospondin module are inactive against aggrecan55,58e60.
Mature ADAMTS-4 and -5 containing a full suite of C-terminal
ancillary domains are the most active species in vitro and, in the
absence of heparin34, engineered deletions of C-terminal domains
diminish catalytic activity against both the IGD and chondroitin
sulphate (CS)-rich regions of aggrecan59. In these studies with
recombinant enzymes expressed in HEK293-EBNA cells, deletion of
the spacer domain of ADAMTS-4 or the cysteine-rich domain of
ADAMTS-5 ablates aggrecan-degrading activity by more than 95%,
while having only minor effects on cleavage of non-aggrecan
substrates such as ﬁbromodulin59.
It is possible that C-terminal processing of ADAMTS-4might have
different effects in other cell types, sinceGao et al.have used a human
chondrosarcoma cell line stably transfected with ADAMTS-4 and
MT4-MMP, to show that the most active form of ADAMTS-4 is
generated by MT4-MMP-mediated removal of the spacer domain54.
The authors propose that sites at Lys694Y 695Phe and Thr581Y 582Phe
in the spacer domain are susceptible to MT4-MMP cleavage.
There is also evidence that C-terminal processing inﬂuences
tissue localisation of aggrecanases. ADAMTS-5 in normal human
cartilage localises around cells in the superﬁcial zone and around
clonal clusters in OA cartilage16. The pericellular localisation is
thought to occur via HA binding to the disintegrin domain16 and to
a heparin-binding motif in the spacer domain. Other studies in
HTB-94 chondrosarcoma cells show that the cysteine-rich domain
of ADAMTS-5 is essential for binding and localisation in the
extracellular matrix59. In ADAMTS-4, it is the spacer domain that
mediates matrix binding56,57,60,61. Thus, C-terminal processing can
inﬂuence aggrecanase activity directly via its effects on enzyme
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extracellular matrices.
Proteinases that cleave ADAMTS C-terminal domains include
MT4-MMP54, PACE452 and ADAMTS-4 and -5 themselves56. In
addition, two putative PC cleavage sites are located at RRTR565 and
RKFR696 in ADAMTS-448. The presence of two established and two
putative C-terminal cleavage sites, combined with apparent
susceptibility of ADAMTS enzymes to at least three different
families of proteinases, suggests that ADAMTS-4 and -5 C-terminal
processing is a key mechanism for regulating aggrecanase activity.
In addition to proteolysis, alternative splicing of ADAMTS-4
provides another means of disrupting C-terminal ancillary domains
to modulate enzyme activity27.
Regulation of ADAMTS-4 and -5 activities by glycosylation:
enzyme and substrate
Almost all secreted proteins undergo some form of post-trans-
lational modiﬁcation and the most common type of modiﬁcation is
glycosylation. In many cases glycosylation confers essential func-
tional properties on secreted proteins. All ADAMTS proteinases are
predicted to be glycoproteins carrying at least one mannose modi-
ﬁcation on tryptophan residues within prescribed motifs in the ﬁrst
thrombospondin motif62. This prediction has been conﬁrmed
experimentally for ADAMTS-5 in studies which identiﬁed two C-
mannose substitutions as well as a glucose-fucose disaccharide on
the thrombospondin domain of recombinant enzyme62. Two sites
for C-mannosylation are also predicted for the thrombospondin
domain of ADAMTS-4. N-linked glycosylation in the ADAMTS-5
spacer domainwas predicted2 and has been conﬁrmed in a separate
study by a change in electrophoretic mobility of recombinant
ADAMTS-5 after digestion with PNGase F55. There is no evidence
that ADAMTS-4 carries N-linked glycosylation63 and there is no
evidence that underglycosylation affects ADAMTS-4 or -5 activity.
Mannosylation in the thrombospondin domain regulates secretion
of some members of the ADAMTS family62. It is possible that
secretion of ADAMTS-4 and -5 is also inﬂuenced by mannosylation.
ADAMTS enzymes degrade aggrecan extracellularly so controlling
their secretion will affect aggrecanase activity directly.
Glycosylation of the aggrecan substrate is another variable that
markedly affects aggrecanase activity. The signature activity of the
aggrecanases is cleavage within the IGD. The IGD contains keratan
sulphate (KS) but no CS substitutions, so it is not surprising that
removal of KS alone blocks aggrecanase cleavage in the IGD64e66.
The KS content of human aggrecan increases from a minimal
percentage at birth, to over a quarter of the glycosaminoglycan
content at maturity, and KS microstructure also changes dramati-
cally during this time67. In addition, the microstructure of KS in the
IGD is distinctly different to the microstructure of KS elsewhere on
aggrecan68, suggesting that KS microstructure might contain
functional information. Furthermore, whereas ADAMTS-5 cleavage
in the IGD is highly efﬁcient in both mature and juvenile cartilage,
ADAMTS-4 cleavage in the IGD is inefﬁcient in juvenile carti-
lage64,69. Collectively these studies suggest an intriguing link
between increased susceptibility to aggrecanolysis with ageing,
and increased KS substitutionwith ageing. Further work is required
to investigate this potential link and to determine whether
ADAMTS-4 and -5 have age-speciﬁc functions in cartilage and OA.
Inhibitors and enhancers of ADAMTS-4 and -5 activity
Inhibitors of ADAMTS-4 and -5 activity
Once aggrecanase enzymes have been synthesised, secreted
from the cell, activated by prodomain removal and modiﬁed byC-terminal processing, their activity can be further modiﬁed by
endogenous inhibitors. The Tissue Inhibitor of MetalloProteinases
(TIMP) family of inhibitors are expressed in joint tissues, and are
regulated in arthritis. Of the four family members, TIMP-3 is the
most potent inhibitor of both ADAMTS-470,71 and ADAMTS-570 and
there is negligible inhibition of aggrecanases by TIMPs-1, -2 or -470.
In the TIMP-3 null mouse there is increased aggrecan loss and
increased NITEGE373 neoepitope, concomitant with mild cartilage
degradation72, suggesting that TIMP-3 is indeed an endogenous
aggrecanase inhibitor. TIMP-3 binds tightly to negatively charged
glycosaminoglycans73 and TIMP-3 potency against ADAMTS-4 is
enhanced by ADAMTS-4 binding to aggrecan74; it appears that
TIMP-3 has a greater afﬁnity for ADAMTS-4 complexed with
aggrecan, than it does for ADAMTS-4 alone74. A recent, exciting
ﬁnding is that TIMP-3 potency against ADAMTS-4 and -5 is greatly
enhanced in the presence of calcium pentosan polysulphate
(CaPPS)75. CaPPS itself inhibits aggrecanase activity via interactions
with the spacer domain of ADAMTS-4 and the cysteine-rich domain
of ADAMTS-575. The levels of TIMP-3 in cartilage are very lowdue to
rapid internalisation by the cell via Lipoprotein receptor-related
proteins (LRP)-mediated endocytosis75.
Other proteinase inhibitors in cartilage include a2-macroglob-
ulin and the membrane-anchored glycoprotein, reversion-inducing
cysteine-rich protein with Kazal motifs (RECK). a2-macroglobulin
inhibits ADAMTS-4 and -5 in vitro by trapping the enzymes in a 1:1
complex76, however, there is no evidence for such a complex in
synovial ﬂuid, nor evidence that a2-macroglobulin is cleaved by
either enzyme76. Similarly, there is no evidence that RECK inhibits
ADAMTS-4 or -5. Thus, Timp-3 appears to be the only endogenous
inhibitor of aggrecanase activity in cartilage. Interestingly,
ADAMTS-4 activity is blocked when the C-terminal domain of
ﬁbronectin binds the ADAMTS-4 spacer domain61. Enzyme inhibi-
tion following interactions between ﬁbronectin and ADAMTS-4
could be relieved by C-terminal processing of ADAMTS-4 to
displace ﬁbronectin or ﬁbronectin fragments. The concentrations of
ﬁbronectin and ﬁbronectin fragments are increased in OA and
rheumatoid synovial ﬂuids.
Enhancers of ADAMTS-4 and -5 activity
There is potential for increased aggrecanase activity following
interactions between ADAMTS enzymes and other cell surface or
extracellular matrix molecules. For example, the interaction of
ADAMTS-177 and ADAMTS-578 with the matrix molecule ﬁbulin-l
increases catalytic activities toward aggrecan or versican
substrates, respectively. Fibulin-1 itself is not a substrate for these
enzymes. The C-terminal thrombospondin domain of ADAMTS-1
interacts with ﬁbulin-1, however, it is not clear which domain(s) of
ADAMTS-5 might interact with ﬁbulin. The epidermal growth
factor (EGF)-like repeats in domain II of ﬁbulin-1 interact speciﬁ-
cally with the G3 domain of aggrecan79, and since aggrecan is
a major ADAMTS-5 substrate, the interaction between ﬁbulin-1 and
ADAMTS-5 might provide a mechanism for localising ADAMTS-5 in
close proximity with its substrate.
Recent in vitro studies have shown that ADAMTS-5 interacts
directly with syndecan-4, and mice deﬁcient in syndecan-4 are
protected against aggrecan loss and cartilage damage in a running
wheel model of joint damage80. These results suggest that synde-
can-4 might enhance ADAMTS-5 activity, however the mechanism
is unknown. Perhaps syndecan-4 is required to tether ADAMTS-5 to
the cell surface80, reminiscent of the model in which syndecan-1 is
thought to tether ADAMTS-4 to the cell surface54. High molecular
weight HA is also thought to have a role in sequestering ADAMTS-5
in the pericellular matrix of OA cartilage16. No complexes between
HA and ADAMTS-4, or HA and ADAMTS-9, have been detected in
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syndecan-4 and syndecan-1 enhance aggrecanase activity, not via
their interactions with ADAMTS-4 or -5, but by virtue of anchoring
these enzymes at their sites of action and limiting their ability to
diffuse away. ADAMTS-4 and -5 are certainly diffusible enzymes;
ADAMTS-4 and -5 synthesised by mouse synovial ﬁbroblasts in co-
cultures can penetrate and degrade aggrecan within femoral head
cartilage explants29. Together these ﬁndings suggest ﬁrstly, that
there are mechanisms for helping to colocalise aggrecanase
enzymes with aggrecan substrate and secondly, that ADAMTS
activity detected in one joint tissue might be the product of
ADAMTS mRNA produced in a different joint tissue.
Perspectives and challenges for the future
Aggrecanase research to date has been hampered by two, major,
technical limitations. The ﬁrst is the inability to measure the
products of aggrecanase activity in patient serum or urine. In this
issue of Osteoarthritis and Cartilage, Thirunavukkarasu and
colleagues describe successful reverse engineering of the original
aggrecanase neoepitope antibody, BC381. The authors have gener-
ated antibody BC3-C2 with a 4-log improvement in afﬁnity for the
374ARGS neoepitope82. The sensitivity and speciﬁcity of this new
antibody will enable the measurement of aggrecanase fragments in
human serum and urine by ELISA assay and facilitate clinical testing
of aggrecanase inhibitors. However BC3-C2will not solve the thorny
issue of identifying the human aggrecanase. The second technical
limitation is that we have no methods at all for distinguishing the
products of ADAMTS-4 activity, from the products of ADAMTS-5
activity; clearly, because the products are identical. At present this
limitation seems insurmountable; we are stymied on this front!
And to complicate matters further, there is a third aggrecan-
degrading enzyme that cleaves at the well-recognised aggrecanase
cleavage sites in the CS-rich region. This enzyme cleaves at the
Glu1279Y 1280Gly and Glu1467Y 1468Gly aggrecanase sites in the CS-
rich region of mouse aggrecan and its activity is detected in the
ADAMTS-4/5 double-deﬁcient mouse83. While this third aggreca-
nase is unlikely to be the aggrecanase in humans, it is nevertheless
important that the enzyme be identiﬁed and characterised. If it has
a role in OA pathology, then it will be necessary to inhibit this
enzyme along with ADAMTS-4 and/or ADAMTS-5. Conversely, if it
has a role in normal skeletal development and endochondral ossi-
ﬁcation, it will be important to ensure that aggrecanase inhibitors
currently in development do not inhibit this enzyme.
Despite intensive research over the last decade we are still
unable to positively identify the human aggrecanase and indeed
the possibility remains that both ADAMTS-4 and ADAMTS-5 play
equally important roles in aggrecanolysis. In this editorial we have
highlighted the difﬁculties in ﬁnding deﬁnitive answers to this
quandary; the regulation of ADAMTS-4 and -5 enzymes is complex
and there are signiﬁcant pre- and post-transcriptional events that
contribute to the ﬁnal level of enzyme activity. These are likely to be
dynamic events that are themselves under tight control. The
simplest and most abundant studies have examined regulation of
ADAMTS-4 and -5 mRNA expression, comparing OA cartilage with
normal cartilage, or the regulatory effects of cytokines, growth
factors and other exogenous modulators, in vitro. However, we
caution that no reliable conclusions about the source of the
aggrecanase activity can bemade frommRNA studies, either in vitro
or in vivo; the number and range of processes (Fig. 1) that deter-
mine the ﬁnal level of ADAMTS-4 or ADAMTS-5 activity is signiﬁ-
cant, and likely to overwhelm the effects of increased or decreased
mRNA expression, making absolute conclusions about the
contributing aggrecanase doubtful. Although ADAMTS-4 mRNA is
reproducibly upregulated by cytokines in a number of experimentalsystems, it is important to counter that in the same or similar
systems, ADAMTS-5 is often expressed at much higher levels than
ADAMTS-4, and that ADAMTS-5 has a 30-fold greater intrinsic
activity than ADAMTS-434. Accordingly, the dilemma of identifying
the human aggrecanase remains.
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